Artículos por temáticas

Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease.

Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, Caldwell KA, Caldwell GA, Standaert DG.

Cell Death Dis. 2010;1:e2. doi: 10.1038/cddis.2009.4.

A new approach for the quantitative evaluation of the clock drawing test: preliminary results on subjects with Parkinson's disease.

De Pandis MF, Galli M, Vimercati S, Cimolin V, De Angelis MV, Albertini G.

Neurol Res Int. 2010;2010:283890. doi: 10.1155/2010/283890.

Parkinson's disease: is it a toxic syndrome?

Gad Elhak SA, Ghanem AA, Abdelghaffar H, El Dakroury S, Salama MM.

Neurol Res Int. 2010;2010:103094. doi: 10.1155/2010/103094.

Neuroprotective properties of mildronate, a small molecule, in a rat model of Parkinson's disease.

Klusa VZ, Isajevs S, Svirina D, Pupure J, Beitnere U, Rumaks J, Svirskis S, Jansone B, Dzirkale Z, Muceniece R, Kalvinsh I, Vinters HV.

Int J Mol Sci. 2010 Nov 9;11(11):4465-87. doi: 10.3390/ijms11114465.

α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.

Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M.

Int J Mol Sci. 2010 Oct 29;11(11):4257-66. doi: 10.3390/ijms11114257. Review.

Detection of impulse control disorders in Parkinson disease patients.

Weiss HD, Hirsch ES, Williams JR, Swearengin L, Marsh L.

Neurologist. 2010 Nov;16(6):406-7. doi: 10.1097/NRL.0b013e3181e8868b. No abstract available.

An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.

Laganiere J, Kells AP, Lai JT, Guschin D, Paschon DE, Meng X, Fong LK, Yu Q, Rebar EJ, Gregory PD, Bankiewicz KS, Forsayeth J, Zhang HS.

J Neurosci. 2010 Dec 8;30(49):16469-74. doi: 10.1523/JNEUROSCI.2440-10.2010.

Neurodegenerative disease: Pieces of the Parkinson's puzzle.

Ozawa Y.

Nat Rev Neurosci. 2010 Dec;11(12):787. No abstract available.

A readability assessment of online Parkinson's disease information.

Fitzsimmons PR, Michael BD, Hulley JL, Scott GO.

J R Coll Physicians Edinb. 2010 Dec;40(4):292-6. doi: 10.4997/JRCPE.2010.401.

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

Politis M.

BMC Med. 2010 Dec 2;8:80. doi: 10.1186/1741-7015-8-80.

Wolff-Parkinson-White syndrome and rheumatic mitral stenosis--an uncommon association.

Maheshwari M, Mittal SR.

J Assoc Physicians India. 2010 Jun;58:388-90.

CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.

Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A.

PLoS One. 2010 Nov 24;5(11):e15522. doi: 10.1371/journal.pone.0015522.

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI.

J Neurosci. 2010 Dec 1;30(48):16284-92. doi: 10.1523/JNEUROSCI.2590-10.2010.

Olfactory FMRI in patients with Parkinson's disease.

Hummel T, Fliessbach K, Abele M, Okulla T, Reden J, Reichmann H, Wüllner U, Haehner A.

Front Integr Neurosci. 2010 Oct 28;4:125. doi: 10.3389/fnint.2010.00125.

Parkinson's disease: general features, effects of levodopa treatment and future directions.

Freire MA, Santos JR.

Front Neuroanat. 2010 Nov 17;4:146. doi: 10.3389/fnana.2010.00146. No abstract available.